Definium Therapeutics is a clinical-stage biotechnology company working at the intersection of healthcare, pharmaceuticals, and neuroscience. Its research centers on precision therapeutics derived from psychedelic compounds, including pharmaceutically optimized lysergide (LSD) and an R-enantiomer of MDMA. The company is developing these candidates for psychiatric and neurodevelopmental conditions such as major depressive disorder, generalized anxiety disorder, and core symptoms of autism spectrum disorder, progressing its programs through preclinical and clinical research.